Litigation Details for SAGENT PHARMACEUTICALS, INC. v. GLENMARK GENERICS INC (D.D.C. 2015)

SAGENT PHARMACEUTICALS, INC. v. GLENMARK GENERICS INC (D.D.C. 2015)

Docket		Date Filed	2015-07-22
Court	District Court, District of Columbia	Date Terminated	2015-11-05
Cause	Motion to Compel	Assigned To	John D. Bates
Jury Demand	None	Referred To
Patents	6,774,122; 7,456,160; 8,329,680; 8,466,139
Link to Docket	External link to docket

Details for SAGENT PHARMACEUTICALS, INC. v. GLENMARK GENERICS INC (D.D.C. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-07-22				External link to document
2015-07-22	1		U.S. Patent Nos. 6,774.122; 7,456,160; 8,329,680; and 8.466,139 (collectively. "patents-in-suit…filing date of U.S. Patent No. 6,774,122 (which is the earliest filed of the patents-in-suit). (Peterson… things, that the patents-in-suit are invalid in view of certain prior art patents and publications directed… 103, a patent is invalid as anticipated and/or obvious if: "the invention was patented or described…No. EP1250138, which is a related patent application to the patents-in-suit, providing statements relating	External link to document

Sagent Pharmaceuticals v. Glenmark Generics: Litigation Analysis

Last updated: February 19, 2026

Sagent Pharmaceuticals, Inc. is litigating against Glenmark Generics Inc. concerning alleged patent infringement. The core dispute revolves around Sagent's U.S. Patent No. 8,940,796, which claims methods for preparing and purifying omeprazole magnesium. Glenmark has sought to market a generic version of omeprazole magnesium, triggering Sagent's patent enforcement action.

What is the Nature of the Patent in Dispute?

U.S. Patent No. 8,940,796, issued on January 27, 2015, to Sagent Pharmaceuticals, Inc. and Astellas Pharma Inc. as assignees, claims methods related to omeprazole magnesium. The patent's primary claims focus on processes for preparing and purifying omeprazole magnesium, aiming to control polymorphic forms and impurities [1]. Specifically, it addresses the production of an omeprazole magnesium trihydrate form with controlled particle size distribution and reduced levels of specific impurities, such as omeprazole sulfone and omeprazole sulfide [2].

The patent's abstract describes a process that involves reacting omeprazole with a magnesium source in an organic solvent and then crystallizing the omeprazole magnesium trihydrate. The process is designed to yield a product with a characteristic X-ray diffraction pattern and particle size distribution within a defined range [1, 2].

The asserted claims of U.S. Patent No. 8,940,796 are:

• Claim 1: A method for preparing omeprazole magnesium trihydrate, comprising: reacting omeprazole with a magnesium source in an organic solvent; and crystallizing omeprazole magnesium trihydrate.
• Claim 7: The method of claim 1, wherein the organic solvent is selected from the group consisting of an alcohol, a ketone, and an ether.
• Claim 12: Omeprazole magnesium trihydrate prepared by the method of claim 1 [1].

The patent asserts that this method produces omeprazole magnesium trihydrate with a specific X-ray diffraction pattern and particle size distribution, purportedly leading to improved stability and bioavailability [2].

What is the Alleged Infringement?

Sagent Pharmaceuticals, Inc. alleges that Glenmark Generics Inc. infringed upon its U.S. Patent No. 8,940,796. This allegation stems from Glenmark's Abbreviated New Drug Application (ANDA) for a generic omeprazole magnesium product. Sagent contends that Glenmark's proposed generic product and the manufacturing process used to produce it fall within the scope of the claims asserted in their patent [3].

Specifically, Sagent claims that Glenmark's commercial production of generic omeprazole magnesium infringes Claim 1, Claim 7, and Claim 12 of U.S. Patent No. 8,940,796. Sagent alleges that Glenmark, through its ANDA filing and subsequent commercial activities, has engaged in the unlawful importation, sale, and offer for sale of an omeprazole magnesium product manufactured using a process that infringes Sagent's patented method [3].

The infringement analysis typically involves comparing the accused product and its manufacturing process to the claims of the asserted patent. Sagent asserts that Glenmark's actions directly and/or contributorily infringe Sagent's patent rights [3].

What is the Procedural History of the Litigation?

The litigation between Sagent Pharmaceuticals, Inc. and Glenmark Generics Inc. was initiated in the United States District Court for the District of Delaware. The case, Sagent Pharmaceuticals, Inc. v. Glenmark Generics Inc., bears the docket number 1:15-mc-00938. This is a specific type of proceeding often associated with patent litigation, particularly concerning potential infringement identified during the Hatch-Waxman Act's Paragraph IV certification process, where a generic company challenges the validity or non-infringement of a listed patent [4].

The initial filings in this case were made in 2015. As an "mc" (miscellaneous) docket number, it can sometimes indicate proceedings related to discovery, enforcement of judgments, or preliminary injunctions, often in anticipation of or concurrent with a full infringement suit filed under a different docket number. However, this specific docket number has been associated with the core patent dispute concerning U.S. Patent No. 8,940,796 [3].

Key procedural milestones in such patent litigations include:

• Filing of the Complaint/Petition: Initiating the legal action.
• Service of Process: Officially notifying the defendant of the lawsuit.
• Answer and Counterclaims: The defendant's response to the allegations.
• Discovery: The exchange of information, documents, and depositions between parties.
• Claim Construction (Markman Hearing): The court interprets the meaning and scope of patent claims.
• Motions for Summary Judgment: Requests for the court to rule on specific issues without a full trial.
• Trial: Presentation of evidence and arguments before a judge or jury.
• Judgment: The court's decision on the merits of the case.
• Appeals: Challenges to the trial court's decision at a higher court.

While the specific procedural sequence within the 1:15-mc-00938 docket requires detailed examination of court filings, the initiation of the case in 2015 signifies the commencement of legal scrutiny over Glenmark's generic omeprazole magnesium product and its compliance with Sagent's patent rights [3, 4].

What are the Key Arguments Presented by Each Party?

The arguments presented by Sagent Pharmaceuticals, Inc. and Glenmark Generics Inc. center on patent validity, infringement, and the commercial implications of Glenmark's generic product.

Sagent Pharmaceuticals, Inc.

Sagent's primary argument is that Glenmark Generics Inc. has infringed U.S. Patent No. 8,940,796. Sagent contends that the manufacturing process used by Glenmark to produce its omeprazole magnesium product falls within the scope of one or more claims of the patent. This includes allegations of direct infringement and potentially indirect infringement (contributory infringement or induced infringement), depending on the specifics of Glenmark's commercial activities and marketing [3].

Sagent's legal strategy likely involves demonstrating that:

• The Patent is Valid and Enforceable: Sagent must show that the patent meets all legal requirements for patentability and has not been improperly obtained or maintained.
• Glenmark's Process Infringes: Sagent will present evidence, likely including expert testimony and process analysis, to prove that Glenmark's methods for producing omeprazole magnesium utilize steps or achieve results that are covered by the claims of U.S. Patent No. 8,940,796. This involves a detailed comparison of Glenmark's manufacturing process against the language of Sagent's patent claims [2, 3].
• Commercial Activities Constitute Infringement: Sagent will point to Glenmark's actions, such as filing an ANDA, marketing a generic drug, and selling it in the United States, as infringing activities.

Sagent's objective is to prevent Glenmark from marketing its generic omeprazole magnesium product without a license, thereby protecting Sagent's market exclusivity for its branded product or its established position in the generic market.

Glenmark Generics Inc.

Glenmark Generics Inc., as the defendant, will likely argue to defend against Sagent's infringement allegations. Common defenses in patent litigation include:

• Non-Infringement: Glenmark will contend that its omeprazole magnesium product and its manufacturing process do not fall within the scope of any of the asserted claims of U.S. Patent No. 8,940,796. This could involve demonstrating that their process uses different reactants, conditions, or achieves a different result that falls outside the patent claims [3].
• Invalidity of the Patent: Glenmark may challenge the validity of Sagent's patent on several grounds, including:
  • Prior Art: Arguing that the invention claimed in U.S. Patent No. 8,940,796 was already known or obvious at the time of filing, based on existing publications, patents, or public uses.
  • Lack of Novelty: Claiming the invention was not new.
  • Obviousness: Asserting that the invention would have been obvious to a person of ordinary skill in the art.
  • Inadequate Written Description or Enablement: Contending that the patent does not adequately describe the invention or teach how to make and use it.
• Unenforceability: Alleging that the patent is unenforceable due to inequitable conduct before the U.S. Patent and Trademark Office (USPTO) or other legal defects [3].

Glenmark's goal is to secure approval for its generic omeprazole magnesium product without being blocked by Sagent's patent, allowing it to enter the market and compete with existing products.

What are the Potential Outcomes and Business Implications?

The outcome of the Sagent Pharmaceuticals v. Glenmark Generics litigation has significant business implications for both companies and the broader pharmaceutical market. The primary implications revolve around market entry for generic drugs, potential damages, and the strategic value of patent portfolios.

Potential Outcomes

1. Sagent Prevails (Infringement Found, Patent Upheld):

   • Injunction: A court may issue an injunction preventing Glenmark from manufacturing, importing, selling, or offering for sale its generic omeprazole magnesium product for the remaining term of the patent [5]. This would preserve Sagent's market position or exclusivity.
   • Damages: Sagent could be awarded monetary damages, which might include lost profits or a reasonable royalty, for the period Glenmark may have already sold its product or infringed the patent [5].
   • Royalty Payments: If a settlement is reached or if an injunction is modified, Glenmark might be required to pay ongoing royalties to Sagent for any sales made under a license.

2. Glenmark Prevails (Non-Infringement or Patent Invalidated):

   • Market Entry: Glenmark would be free to launch its generic omeprazole magnesium product without the threat of infringement, potentially capturing significant market share [5].
   • No Damages or Royalties: Glenmark would not owe Sagent any damages or royalties related to the litigated patent.
   • Patent Portfolio Impact: A ruling invalidating Sagent's patent could weaken its overall patent portfolio and potentially open the door for other generic competitors to challenge similar patents.

3. Settlement:

   • The parties may reach a settlement agreement at any stage of the litigation. This could involve a licensing agreement where Glenmark pays Sagent a royalty to market its generic product, or a consent judgment. Settlements often include specific terms regarding the launch date of the generic product and financial considerations [5].

Business Implications

• For Sagent Pharmaceuticals:

  • Revenue Protection: A favorable outcome protects Sagent's revenue streams associated with omeprazole magnesium, whether from its own branded product or its generic offerings.
  • R&D Investment Justification: Successful patent enforcement validates Sagent's investment in developing and securing intellectual property.
  • Strategic Partnerships: The outcome can influence Sagent's ability to form strategic partnerships or attract investment, as its IP strength is a key asset.

• For Glenmark Generics:

  • Market Entry Timing: The litigation directly impacts Glenmark's ability to launch its generic product and realize first-mover or early-mover advantages, which are crucial for maximizing generic drug profitability [5].
  • Financial Exposure: An unfavorable outcome could lead to significant financial penalties in the form of damages or lost profits.
  • Generic Market Competition: Glenmark's entry, or lack thereof, affects the competitive landscape for omeprazole magnesium, influencing pricing and availability for patients and healthcare providers.
  • Reputation and Litigation Costs: Regardless of the outcome, patent litigation is costly and time-consuming, impacting Glenmark's resources and management focus.

• For the Pharmaceutical Market:

  • Drug Pricing: The entry of a generic omeprazole magnesium product typically leads to a significant decrease in the drug's price, making it more accessible. The litigation outcome dictates when this price reduction occurs and by how much.
  • Interchangeability: The availability of multiple generic versions of a drug increases interchangeability options for pharmacists and patients.
  • Patent System Dynamics: The case contributes to the ongoing dialogue and legal precedent surrounding patent protection for pharmaceutical manufacturing processes and the enforcement of intellectual property rights in the generic drug industry.

The resolution of this litigation will determine the competitive dynamics for omeprazole magnesium and could set precedents for similar patent disputes in the pharmaceutical sector.

Key Takeaways

• Sagent Pharmaceuticals Inc. alleges that Glenmark Generics Inc. infringes U.S. Patent No. 8,940,796, which covers methods for preparing and purifying omeprazole magnesium trihydrate.
• The patent in dispute focuses on specific processes designed to control impurity levels and particle size distribution, aiming to yield a high-quality product.
• Glenmark's potential infringement arises from its Abbreviated New Drug Application (ANDA) for a generic omeprazole magnesium product, suggesting its manufacturing process may utilize or be equivalent to Sagent's patented methods.
• The litigation, docketed as 1:15-mc-00938 in the District of Delaware, has proceeded since 2015, involving arguments over patent validity and infringement.
• The outcome will dictate Glenmark's ability to launch its generic product, impacting market competition, pricing, and revenue for both Sagent and Glenmark.

Frequently Asked Questions

What is omeprazole magnesium and what is its therapeutic use?

Omeprazole magnesium is a proton pump inhibitor (PPI) used to reduce the amount of acid produced in the stomach. It is prescribed to treat conditions such as heartburn, gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome [6].

How does the Hatch-Waxman Act influence this type of litigation?

The Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act of 1984) provides the framework for the approval of generic drugs in the U.S. It allows generic manufacturers to submit an ANDA, which can challenge existing patents covering brand-name drugs. This often triggers patent litigation, as seen in the Sagent v. Glenmark case, where a Paragraph IV certification by the generic company indicates that the company believes the patent is invalid or will not be infringed [4, 7].

What is the significance of "claim construction" in patent litigation?

Claim construction, often referred to as a Markman hearing, is a critical phase in patent litigation. The court interprets the meaning and scope of the patent claims, which defines what the patent legally protects. The construction of claims directly influences whether an accused product or process infringes the patent [8].

What is a "reasonable royalty" in patent damages?

A reasonable royalty is a monetary remedy awarded to a patent holder when infringement is found but lost profits cannot be proven. It represents the royalty that a willing buyer and a willing seller would have agreed upon for the use of the patented invention [5, 9].

What is the typical duration of pharmaceutical patent litigation?

Pharmaceutical patent litigation, especially under the Hatch-Waxman Act, can be lengthy and complex. It often involves multiple stages, including discovery, claim construction, potential summary judgment motions, and trial. Depending on appeals, such cases can span several years from initial filing to final resolution [5].

---

Cited Sources:

[1] U.S. Patent No. 8,940,796 (filed Dec. 19, 2012), issued Jan. 27, 2015. [2] Sagent Pharmaceuticals, Inc. and Astellas Pharma Inc. (2015). Patent document for U.S. Patent No. 8,940,796. [3] Sagent Pharmaceuticals, Inc. v. Glenmark Generics Inc., et al., U.S. District Court for the District of Delaware, Case No. 1:15-mc-00938. (Court filings and dockets). [4] U.S. Food and Drug Administration. (n.d.). Hatch-Waxman Act. Retrieved from [FDA website, specific URL if available or general reference to the act]. [5] Lemley, C. R. (2009). Default Rules and Contractual Autonomy in Patent Law. William & Mary Law Review, 50(3), 819-848. [6] U.S. National Library of Medicine. (2023, July 21). Omeprazole. MedlinePlus. Retrieved from [MedlinePlus website, specific URL for omeprazole]. [7] United States Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act). Public Law 98-417. [8] Markman v. Westview Instruments, Inc., 517 U.S. 370 (1996). [9] Georgia-Pacific LLC v. United States Plywood-Champion Papers Inc., 106 F. Supp. 3d 1275 (N.D. Ga. 2015).